Jennifer Schneider leads new Centauri appointments

Centauri Therapeutics, a UK-based immunotherapy company focused on the treatment of infectious diseases, has announced three senior appointments at once.

Jennifer Schneider has been named chief executive, Helen Bright has been appointed vice president (VP) of research and development (R&D) and David Roblin becomes chairman of the board of directors.

"An impressive wealth of experience across infectious disease research, drug development and product commercialization"Centauri says that the appointments bring extensive expertise in the discovery, development and commercialization of medicines to treat infectious diseases, and further support the development of its pipeline of novel candidates, built on the Alphamer platform, through to first-in-human trials.